New Ruling Helps Move Mexico Closer to Cannabis Legalization in the Country
SAN DIEGO, CA–(Marketwired – December 14, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that it commends the Mexican senate for voting in favor of extending regulations for certain cannabis products. With the new regulations, more people in need of cannabis and cannabidiol (CBD) for medical care will have more access to products, including our RSHO brand of products.
Medical Marijuana, Inc. subsidiary HempMeds® Mexico’s non-psychoactive, THC-free hemp-based CBD product Real Scientific Hemp Oil-X™ (RSHO-X™) was the first-ever federally approved CBD product in Mexico. Now with the new regulations, it’s a goal for HempMeds® Mexico to bring all their RSHO products into the country to help more customers and provide options.
“These new regulations in Mexico will be a major step forward for the country once they pass the Mexico House of Representatives then signed fully into law. This will also represent a major accomplishment for the cannabis industry as a whole. We are very happy with the outcome and trend that the Mexican Senate put forward with this vote,” stated Chief Executive Officer of Medical Marijuana, Inc., Dr. Stuart Titus. “Our Company has always supported access to all cannabinoids, as we recognize the potential medical advantages they can provide.
“We believe this new legislation in Mexico will increase access to additional cannabis-based products and we will continue encouraging further cannabis reforms by educating doctors and lawmakers on the benefits of cannabinoids — then creating products that can safely and reliably provide our customers with the cannabinoids they seek,” added Dr. Titus.
The new law approves the use of marijuana with therapeutic and medicinal use, with the reforms through General Health Law. This law will allow the access to cannabis based products to treat chronic and degenerative diseases. This law is yet to be approved by the House of Representative, which may be next year.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
HempMeds® which created the first-ever “CBD pipeline” into the United States, is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company. HempMeds offers the US market a wide range of cannabis and CBD products legally across all 50 states.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]